Rheumatology Network's Top 5: FDA Approvals
Check out rheumatology's most groundbreaking FDA approvals of 2021!
FDA Approves Upadacitinib (RINVOQ) for Treatment of Active Psoriatic Arthritis
The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.
Click the image to view the story.
FDA Announces Black Box Warnings for Certain JAK Inhibitors
The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.
Click the image to view the story.
FDA Approves Additional Dose of COVID-19 Vaccine for Immunocompromised Patients
The US Food and Drug Administration (FDA) announced it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems, such as patients with rheumatic disease.
Click the image to view the story.
FDA Approves Anifrolumab-Fnia for Treatment of Systemic Lupus Erythematosus
The US Food and Drug Administration (FDA) announced the approval of anifrolumab-fnia (Saphnelo™) for the treatment of moderate to severe systemic lupus erythematosus.
Click the image to view the story.
FDA Approves Secukinumab for Pediatric Patients with PsA and ERA
Secukinumab is the only biologic treatment in the US that’s approved by the FDA for children and adolescents with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).
Click the image to view the story.